---
title: "Allarity Therapeutics wins key US patent for stenoparib DRP companion diagnostic through 2042"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291279513.md"
description: "Allarity Therapeutics secured a key U.S. patent for its stenoparib DRP companion diagnostic, extending protection through April 2042. The patent covers methods to predict patient benefit from tumor gene-expression profiles, supporting clinical use and U.S. commercialization of stenoparib paired with the DRP test for ovarian cancer. Separate European and Australian protections run until 2039."
datetime: "2026-06-30T12:04:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291279513.md)
  - [en](https://longbridge.com/en/news/291279513.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291279513.md)
generator: "portal-rs"
---

# Allarity Therapeutics wins key US patent for stenoparib DRP companion diagnostic through 2042

-   Allarity Therapeutics received a key U.S. patent for its stenoparib DRP companion diagnostic, extending protection into April 2042. \* Coverage includes methods to predict stenoparib benefit from tumor gene-expression profiles, supporting patient selection in clinical use. \* Exclusivity targets U.S. commercialization of stenoparib when paired with the DRP test, reinforcing its ovarian cancer development strategy. \* Separate patent protection for the stenoparib DRP runs to 2039 in Europe and Australia, with additional markets pending. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED1001210389) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md)

## Related News & Research

- [09:11 ETBioViva Announces U.S. Patent for Klotho Gene Therapy Targeting Age-Related Cognitive Decline](https://longbridge.com/en/news/297657999.md)
- [Kala Bio signs LOI for exclusive US distribution of Virotek ophthalmology genetic tests](https://longbridge.com/en/news/297646733.md)
- [FibroBiologics wins new US patent for degenerative disc disease treatment using fibroblast conditioned media](https://longbridge.com/en/news/297652903.md)
- [Opus Genetics to report Phase 1/2 Cohort 1 topline data for OPGx-BEST1 gene therapy Sept. 9 webcast](https://longbridge.com/en/news/297773739.md)
- [Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentation](https://longbridge.com/en/news/297550820.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**